摘要
目的探讨使用"马利兰+阿糖胞苷+环磷酰胺"(MAC)预处理方案行外周血造血干细胞移植(PBSCT)治疗白血病的临床疗效。方法对我院10例PBSCT治疗的急性白血病患者的临床资料进行分析,预处理采用MAC方案,临床观察药物的不良反应并评估造血重建速度及患者预后。结果 10例患者获得造血重建,未发生预处理相关死亡。移植后5～7d白细胞降为0,中性粒细胞绝对数>0.5×109/L的中位时间为11(8～12)d,无输注血小板计数>20×109/L的中位时间为13(12～13)d;本组平均随访36.8个月(3～100个月),其中3例(30%)患者移植后3个月左右复发。所有患者在移植过程中未出现严重不良反应。结论 MAC预处理方案其不良反应小,优于经典的全身照射/CY方案,且简便易行,抗白血病作用确实可靠,是治疗恶性血液病安全有效的方法。
Objective To explore the use of“busulfan ＋ eytarabine ＋ adenosine cyelophosphate” （MAC） as con- ditioning regimen for allogeneie peripheral blood hematopoietie stem cell transplantation （PBSCT） in the treatment of leukemia clinical curative effect. Methods Hospital 10 eases of PBSCT treatment of acute leukemia clinical data analysis, pretreatment with MAC program, the clinical observation of drug toxicity and to evaluate the hematopoietie reeonstitution and prognosis. Rusults In 10 patients with acquired hematopoietie reconstruction, without preconditioning associated death. After transplanta- tion, 5 ～7d leukocyte reduced to O, absolute neutrophil count 〉0. 5 × 109/L had a median time of 11 （8 ～12） d, no transfu- sion platelet count 〉20 ×109/L had a median time of 13 （ 12～ 13） d; the mean follow - up of 36. 8 months （3 ～ 100 months） , 3 cases （30%） patients 3 months after transplantation or recurrence. All patients in the transplant process without severe adverse reaction. Conclusion MAC pretreatment program of its adverse effects is small, better than the classic body irradiatioa/CY pro- gram, and user - friendly, anti - leukemia effect of reliable, safe and effective treatment of hematological malignancies ap- proach.
出处
《实用心脑肺血管病杂志》
2012年第12期1987-1988,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
造血干细胞移植
白血病
白消安
阿糖胞苷
环磷酰胺
治疗结果
Hematopoietic stem cell transplantation
Leukemia
. Busulfan
Cyclophosphamide
Cyclic adenosine phosphate
Treatment outcome
